Fate Therapeutics (Fate Therapeutics) Inventory-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Fate Therapeutics Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Fate Therapeutics's Average Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil. Fate Therapeutics's Revenue for the three months ended in Dec. 2023 was $1.68 Mil. Fate Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.

Fate Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 stayed the same from Sep. 2023 (0.00) to Sep. 2023 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Fate Therapeutics Inventory-to-Revenue Historical Data

The historical data trend for Fate Therapeutics's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fate Therapeutics Inventory-to-Revenue Chart

Fate Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory-to-Revenue

Get a 7-Day Free Trial

Fate Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Inventory-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Fate Therapeutics's Inventory-to-Revenue

For the Biotechnology subindustry, Fate Therapeutics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fate Therapeutics's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's Inventory-to-Revenue falls into.

Fate Therapeutics Inventory-to-Revenue Calculation

Fate Therapeutics's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (A: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )
=	( (0	+	0)	/	1 )	/	63.533
=	0					/	63.533
=	0.00

Fate Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (Q: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Revenue (Q: Dec. 2023 )
=	( (0	+	0)	/	1 )	/	1.676
=	0					/	1.676
=	0.00

Fate Therapeutics (NAS:FATE) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Fate Therapeutics's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Fate Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	0	/	0
	=

Fate Therapeutics Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Fate Therapeutics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Fate Therapeutics (Fate Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fate Therapeutics Inc (NAS:FATE) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

F6T:Germany F6T:Germany

Address

12278 Scripps Summit Drive, San Diego, CA, USA, 92131

Website

https://www.fatetherapeutics.com

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Executives

J Scott Wolchko	director, officer: President and CEO	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Dulac Edward J Iii	officer: Chief Financial Officer	FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Bahram Valamehr	officer: Chief Development Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121
Cindy Tahl	officer: See Remarks	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Yuan Xu	director	C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Brian T. Powl	officer: Chief Commercial Officer	C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131
Yu-waye Chu	officer: See Remarks	FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
John Mendlein	director
Mark Plavsic	officer: Chief Technical Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Shefali Agarwal	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Karin Jooss	director	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Timothy P Coughlin	director	339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Robert Hershberg	director	3005 FIRST AVENUE, SEATTLE WA 98121
Robert S Epstein	director